Lite Strategy (LITS) AI Stock Analysis

• Market Cap: $42.91M
• Dividend Yield: N/A
• Average Volume (3M): 307.45K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.71
• Revenue Growth: N/A
• EPS Growth: 81.20%
• Country: US
• Employees: 4
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.82
• Shares Outstanding: 36,362,000
• 10 Day Avg. Volume: 262,673
• 30 Day Avg. Volume: 307,449
• PEG Ratio: <0.01
• Price to Book (P/B): 1.78
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.45
• Enterprise Value/Market Cap: 0.81
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -2.74
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -3.71
• Revenue Forecast (FY): $25.00M

• Rating: 46 Neutral
• Price Target: $1.00 ▼(-24.81% Downside)
• Action: Reiterated Date: 03/24/26
• Date: Action: Reiterated 03/24/26

The score is primarily constrained by weak financial performance (sharp 2025 reversal to losses with zero revenue and sustained cash burn). Technical indicators are mostly neutral but do not offset the longer-term downtrend. Valuation is also pressured by loss-making results and no dividend support.

Positive Factors

No reported debt; strong balance-sheet flexibility

The absence of reported debt and roughly $81.9M of TTM equity provides durable financial flexibility to fund R&D, operations, or strategic pivots without immediate leverage. This reduces refinancing risk and preserves optionality over the next several quarters.

Demonstrated ability to generate revenue and profit (FY2024)

FY2024 profitability shows the business can achieve meaningful revenue and positive margins under the right conditions. That historical operating capability supports the view that revenue recovery is possible if product-market fit and execution are restored.

Management and governance continuity with formal CEO agreement

A formal CEO employment agreement and defined incentive package align leadership with shareholders and support continuity. Combined roles and explicit equity/bonus provisions improve retention and provide clearer accountability for medium‑term execution.

Negative Factors

Zero TTM revenue and large net loss

Reporting zero TTM revenue while incurring roughly a $39.7M net loss signals a structural inability to monetize offerings today. This undermines self‑sufficiency, increases reliance on external capital, and heightens risk to sustainable operations absent clear revenue catalysts.

Ongoing negative cash flow / cash burn

Persistent negative operating and free cash flow (~-$12.2M TTM) shows the company is not self‑funding and is steadily burning cash. Over a multi‑month horizon this necessitates financing or cuts, limiting investment in commercialization and increasing dilution risk.

Earnings volatility and execution risk

Large swings from FY2024 profitability to FY2025 and TTM losses reflect unstable execution and earnings quality. This volatility hampers forecasting, weakens partner/customer confidence, and increases the likelihood the company will need external funding to bridge performance gaps.

Lite Strategy Business Overview & Revenue Model

Company Description

Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.

Lite Strategy Financial Statement Overview

Summary

Overall financials are high-risk: the income statement swung from strong 2024 profitability to 2025 losses with zero revenue, and cash flow shows multi-year negative operating/free cash flow with further 2025 deterioration. The main offset is low leverage and positive (but declining) equity.

Income Statement

Results are highly volatile. Revenue grew from 2021–2024 (ending at 65.3M in 2024), and 2024 showed strong profitability with healthy operating and net margins. However, 2025 swung sharply negative with zero revenue and a large net loss (-15.9M), reversing the prior year’s profitability. This pattern signals an unstable earnings base and elevated execution risk.

Balance Sheet

Leverage is low, with total debt at 0 in 2024 and 2025 (and only moderate debt in 2022–2023), which reduces financial risk. Equity remains positive (16.9M in 2025), but it has declined meaningfully from prior years, and returns on equity have been negative in most periods (including 2025), reflecting shareholder value pressure from recurring losses and variability in performance.

Cash Flow

Cash generation is weak and inconsistent. Operating cash flow and free cash flow were deeply negative from 2021–2025, with further deterioration in 2025 (free cash flow -20.8M) and negative growth versus the prior year. While 2020 produced positive operating and free cash flow, the multi-year pattern since then suggests significant cash burn and likely ongoing funding needs if conditions do not improve.

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	0.00	0.00	65.30M	48.82M	40.70M	34.80M
Gross Profit	0.00	-368.00K	65.30M	48.82M	40.70M	33.39M
EBITDA	-12.64M	-17.09M	25.82M	-36.38M	-75.16M	-41.02M
Net Income	-39.70M	-15.95M	17.78M	-31.84M	-54.45M	-41.31M
Balance Sheet
Total Assets	82.94M	18.29M	41.38M	120.81M	177.84M	174.10M
Cash, Cash Equivalents and Short-Term Investments	8.76M	18.01M	38.34M	100.69M	153.25M	153.43M
Total Debt	0.00	0.00	0.00	12.73M	9.64M	8.30M
Total Liabilities	1.09M	1.35M	8.36M	96.19M	125.43M	124.63M
Stockholders Equity	81.85M	16.93M	33.02M	24.62M	52.41M	49.47M
Cash Flow
Free Cash Flow	-12.16M	-20.84M	-50.48M	-52.52M	-49.23M	-32.67M
Operating Cash Flow	-12.16M	-20.84M	-50.47M	-52.48M	-48.75M	-31.96M
Investing Cash Flow	-99.43M	35.15M	49.14M	53.69M	6.89M	24.71M
Financing Cash Flow	96.61M	0.00	-11.87M	-40.00K	49.05M	3.47M

Lite Strategy Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.33
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LITS, the sentiment is Negative. The current price of 1.33 is above the 20-day moving average (MA) of 1.17, above the 50-day MA of 1.20, and below the 200-day MA of 2.46, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 50.36 is Neutral, neither overbought nor oversold. The STOCH value of 23.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LITS.

Lite Strategy Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRLD	60 Neutral	$199.09M	-2.24	-129.98%	―	250.00%	15.15%
JSPR	52 Neutral	$33.30M	-0.53	-191.12%	―	―	-24.38%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LITS	46 Neutral	$42.91M	-0.07	-68.86%	―	―	81.20%
GANX	46 Neutral	$72.69M	-2.93	-341.33%	―	―	42.29%
ABVC	41 Neutral	$31.29M	-6.26	-88.89%	―	56.52%	75.22%

Lite Strategy Corporate Events

Lite Strategy Stockholders Approve Directors and Equity Plan

At Lite Strategy, Inc.’s annual meeting held on February 12, 2026, stockholders representing 19,437,130 shares out of 36,785,397 outstanding shares voted on four key governance proposals. Shareholders elected directors Justin J. File and Joshua Riezman to serve until fiscal 2029, signaling continuity in board leadership and long-term oversight.

Investors also approved, on an advisory basis, the compensation of the company’s named executive officers, indicating general support for current pay practices. The meeting further ratified the appointment of CBIZ CPAs as independent auditors for the fiscal year ending June 30, 2026, and approved Lite Strategy’s 2026 Omnibus Equity Compensation Plan, reinforcing the company’s incentive framework and financial reporting stability.

The most recent analyst rating on (LITS) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Lite Strategy stock, see the LITS Stock Forecast page.

Lite Strategy Finalizes New CEO Employment Agreement Terms

On November 14, 2025, Lite Strategy, Inc. appointed Justin J. File as Chief Executive Officer, adding to his existing roles as Chief Financial Officer and Secretary, and on December 23, 2025, the company executed a new employment agreement with him that is effective as of his CEO appointment date and replaces his prior contract. The 2025 employment agreement sets Mr. File’s base salary at $575,000 from October 1, 2025, provides a target annual bonus equal to 50% of base salary starting with the fiscal year beginning July 1, 2025, and confirms his eligibility for standard executive benefits and equity awards, while also detailing severance protections, COBRA reimbursements, pro‑rated bonus, and accelerated or full vesting of stock options in certain termination and change‑in‑control scenarios; he also signed a new proprietary information and inventions agreement replacing his earlier confidentiality arrangement.